Mathieu Choufani

PGY1 @VCU_IMres. MD graduate 2023 - @AUB_lebanon 🇱🇧. BA - Philosophy 2019 🌱. Rheumatology clinical research @BrighamWomens.

[Mathieu Choufani @M_Choufani]

@Shoaib9702 @Hragy @ACCinTouch @escardio @Drlipid Non hdl is just total cholesterol minus hdl, so it just calculates non hdl

[Mathieu Choufani @M_Choufani]

@BlaneyMD The model that generates images is much different than the text model, not as sophisticated!

[Mathieu Choufani @M_Choufani]

@KfouryPeter Best wishes!!

[Mathieu Choufani @M_Choufani]

@AssafJad Best of luck!!

[Mathieu Choufani @M_Choufani]

@theliverdoc Thoughts on plant based protein for the ethical vegans?

[Mathieu Choufani @M_Choufani]

One interesting finding was that only rheumatology and ophthalmology had positive HLA-B27 rates exceeding the expected U.S. general population prevalence when ordering the test— highlighting opportunities to refine testing and referral practices.

[Mathieu Choufani @M_Choufani]

Excited to share our latest publication on HLA-B27 testing in clinical practice, published in The Journal of Rheumatology!

https://t.co/UpB1gO143W

[Mathieu Choufani @M_Choufani]

We analyzed how HLA-B27 testing is used by both rheumatologists and non-rheumatologists across a large healthcare system, focusing on testing patterns, co-testing with other autoantibodies, and referral rates to rheumatology.

[Mathieu Choufani @M_Choufani]

@williamazar_ @NEJM_AI @NIH @PeterPintoMD @charleshesswani @GuKoller @SahilParikh99 @NeilM15 @apkenigsberg @theNCI @NEJM Great work William !

[Mathieu Choufani @M_Choufani]

Our findings underscore the urgent need for multifaceted and intentional recruitment efforts to ensure that clinical trials better represent the populations they aim to serve.

[Mathieu Choufani @M_Choufani]

Excited to share our latest publication on race, ethnicity, and demographic diversity in pivotal psoriatic arthritis (PsA) clinical trials, conducted under the invaluable mentorship of Joerg Ermann and Niti Goel.

https://t.co/Urk7LjmhN9

[Mathieu Choufani @M_Choufani]

We found:

- Reporting of race and ethnicity has generally improved, though many journals only report the % of White participants, often omitting data on other racial and ethnic groups.

[Mathieu Choufani @M_Choufani]

- Underrepresented racial and ethnic groups face challenges such as transportation issues, childcare obligations, mistrust of the healthcare system, provider biases, and other systemic barriers (e.g. poor infrastructure). Our manuscript explores some strategies to address these.

[Mathieu Choufani @M_Choufani]

- Pivotal PsA trials are mostly in North America and Western Europe, with limited representation from Asia, Africa, and Latin America. Recent trial site increases in Eastern Europe and East/Southeast Asia haven't significantly diversified trial populations.

[Mathieu Choufani @M_Choufani]

- Although many PsA trial sites were concentrated in racially and ethnically diverse states like California, Texas, and Florida, this diversity was not reflected in the trial populations. Simply having trial sites in diverse states does not guarantee diverse enrollment.

[Mathieu Choufani @M_Choufani]

- Racial and ethnic diversity in pivotal PsA trials remains limited, with 92% of participants being White. Notably, this figure has shown little to no change from 2000 to 2020.

[Mathieu Choufani @M_Choufani]

@Wissam_Ghusn @dr_aac @OMGhanemMD Fantastic work Wissam!

[Mathieu Choufani @M_Choufani]

@Wissam_Ghusn Great work!!

[Mathieu Choufani @M_Choufani]

@Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates Diversity in axSpA drug trials is improving, but we still have a long way to go.
Greater inclusion by race, ethnicity, gender, and geography is important to ensure trial findings are more applicable to the patients we see in our clinics.

[Mathieu Choufani @M_Choufani]

Excited to share our new publication on demographic & geographic diversity in axial spondyloarthritis drug trials!
We analyzed 59 trials (16,000+ participants) since 2000.
Big thanks to the team @Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates!

https://t.co/zJAFioEs4U

[Mathieu Choufani @M_Choufani]

@Wissam_Ghusn @Spondy_MD @JoergErmann @SPARTAN_Updates - 53 countries enrolled patients, but very few trials in many regions including Sub-Saharan Africa, South/Central Asia, Latin America and the MENA.
- 92% of trials conducted in high-income countries
- Only 2 trials conducted in low or low-middle income countries.